|
|
 |
|
|
| |
Asterion: Corporate Profile
Asterion is developing novel therapeutic products with superior pharmacological profiles that will improve the current treatment options for patients with chronic and debilitating diseases. Our current development candidates are designed to be better than the existing, marketed, best-in-class protein drugs.
In addition to its versatile therapeutic platform technology (ProFuse™), Asterion has an extensive pipeline of third-generation therapeutic protein products in development. Our lead product candidates are third- generation: Growth Hormone (GH) agonists (for treating growth disorders), GH antagonists (for treating acromegaly), AFT™ –EPO (for treating anaemia), and AFT™ –GCSF (for treating neutropenia). 3rd Generation Biopharmaceuticals
The 1st generation biopharmaceuticals such as insulin and EPO where native, recombinantly-derived proteins needing frequent injections. The 2nd generation products such as depot preparations and chemically modified (PEGylated) proteins require more complex manufacture but offer less frequent injections. Our 3rd generation products have the advantages of simple manufacture, potent bioactivity and the potential for significantly less frequent injection.
Asterion: Our MissionAsterion is focussed on exploiting its patented ProFuse™ platform technology to develop a range of third-generation AFT™ therapeutic products that address unmet needs in existing, global commercial markets. We achieve our mission by applying our protein engineering techniques and knowledge of structural biology to create drugs for cytokine-based disorders. Understanding structures like growth hormone (below) helps Asterion engineer superior biological products for human healthcare. Backed by  and The White Rose Seedcorn Fund 
|
|
|
|
|
